TIGIT Inhibitors
May 17, 2024
GSK and iTeos Alliance Boosts Belrestotug Prospects in TIGIT Space
iTeos shares jump by 40%. GSK and iTeos collaboration for Belrestotug looks like a worthy wait. Hopes to ward off the negative sentiments around the volatile TIGIT space? In the ever-evolving landscape of cancer immunotherapy, the pursuit of effective treatment strategies continues to drive innovation and invest...
Read More...
Jan 04, 2022
Accutar’s Phase I clinical trial for AC0176; Bio-Thera’s cancer drug, BAT6005; Nykode’s Covid-19 vaccine trial; Heat Biologics acquires Elusys
FDA approves IND application of Accutar for a prostate cancer treatment trial The US Food and Drug Administration (FDA) has granted Accutar Biotechnology’s Investigational New Drug (IND) application for Phase I clinical trial of AC0176 for treating metastatic castration-resistant prostate cancer (mCRPC). An i...
Read More...
Dec 06, 2021
T-cell Immunoglobulin and ITIM domain (TIGIT) Inhibitor: An Insight into the Pipeline Development Activities, Major Collaborations, and Advancements
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a relatively new immunological checkpoint that has been studied as a potential immunotherapeutic target. TIGIT is a transmembrane glycoprotein receptor containing an Ig-like V-type domain in its cytoplasmic domain and an ITIM in its extracellular domain. It'...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
